Robot-assisted radical prostatectomy (RARP) has become the standard treatment for localized prostate cancer. However, postoperative urinary incontinence and erectile dysfunction remain common complications. A new review published in UroPrecision systematically examines nerve-sparing techniques during RARP, including anatomical foundations, surgical planes, innovative approaches, and patient selection tools, providing a practical guide for balancing cancer control and functional preservation.

A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has uncovered the mechanism underlying how cancer patients respond to a widely used cancer drug, known as paclitaxel, offering insights that may help overcome cancer drug resistance. The study found that small differences in microtubules, the structures inside cells that help the cells divide and move, can determine the efficacy of paclitaxel. This finding was published in Nature Chemical Biology.

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.

Research findings from Sylvester Comprehensive Cancer Center , part of the University of Miami Miller School of Medicine, will be presented at ASCO 2026 – the American Society of Clinical Oncology’s annual meeting in Chicago, May 29-June 2. This tip sheet includes titles and links for 70-plus oral, rapid oral and poster presentations in which Sylvester researchers are involved.

The ERASur (Evaluation of Resection or Ablation for Limited Metastatic Colorectal Cancer) clinical trial has reached a major enrollment milestone, with more than one-third of its targeted patients now accrued, signaling strong momentum for this national study. ERASur (Alliance A022101) is investigating whether adding total ablative therapy—including ablative radiation, surgery, or thermal ablation of all metastatic sites—to standard chemotherapy can improve overall survival compared with chemotherapy alone in patients with newly diagnosed, limited metastatic colorectal cancer.

Researchers from Utah State University, University of Utah Health, the Helmholtz Institute for RNA-based Infection Research and the University of Würzburg report newly discovered details demonstrating how CRISPR Cas12a2 can be repurposed to discriminately kill cancer cells in the petri dish and in mice.